BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11137708)

  • 1. Cell cycle phase specificity in the potentiation of etoposide-induced DNA damage and apoptosis by KN-62, an inhibitor of calcium-calmodulin-dependent enzymes.
    Aoyama M; Grabowski DR; Holmes KA; Rybicki LA; Bukowski RM; Ganapathi MK; Ganapathi R
    Biochem Pharmacol; 2001 Jan; 61(1):49-54. PubMed ID: 11137708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium-calmodulin-dependent processes. Role for effects on apoptosis, DNA cleavable complex, and phosphorylation.
    Kawamura K; Grabowski D; Krivacic K; Hidaka H; Ganapathi R
    Biochem Pharmacol; 1996 Dec; 52(12):1903-9. PubMed ID: 8951349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cell resistance to topoisomerase II poisons: role for intracellular free calcium in the sensitization by inhibitors or calcium-calmodulin-dependent enzymes.
    Grabowski DR; Dubyak GR; Rybicki L; Hidaka H; Ganapathi R
    Biochem Pharmacol; 1998 Aug; 56(3):345-9. PubMed ID: 9744572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apoptosis.
    Vaziri SA; Grabowski DR; Tabata M; Holmes KA; Sterk J; Takigawa N; Bukowski RM; Ganapathi MK; Ganapathi R
    Anticancer Res; 2003; 23(5A):3657-61. PubMed ID: 14666661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
    Ganapathi R; Constantinou A; Kamath N; Dubyak G; Grabowski D; Krivacic K
    Mol Pharmacol; 1996 Aug; 50(2):243-8. PubMed ID: 8700130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.
    Grabowski DR; Holmes KA; Aoyama M; Ye Y; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
    Mol Pharmacol; 1999 Dec; 56(6):1340-5. PubMed ID: 10570063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Ca2+/calmodulin-dependent protein kinase types II and IV, and reduced DNA synthesis due to the Ca2+/calmodulin-dependent protein kinase inhibitor KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenyl piperazine) in small cell lung carcinoma.
    Williams CL; Phelps SH; Porter RA
    Biochem Pharmacol; 1996 Mar; 51(5):707-15. PubMed ID: 8615909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.
    Smith PJ; Souès S; Gottlieb T; Falk SJ; Watson JV; Osborne RJ; Bleehen NM
    Br J Cancer; 1994 Nov; 70(5):914-21. PubMed ID: 7947097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoposide induces G2/M arrest and apoptosis in neural progenitor cells via DNA damage and an ATM/p53-related pathway.
    Nam C; Doi K; Nakayama H
    Histol Histopathol; 2010 Apr; 25(4):485-93. PubMed ID: 20183801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.
    Wang SJ; Peyrollier K; Bourguignon LY
    Arch Otolaryngol Head Neck Surg; 2007 Mar; 133(3):281-8. PubMed ID: 17372087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells.
    Ritke MK; Rusnak JM; Lazo JS; Allan WP; Dive C; Heer S; Yalowich JC
    Mol Pharmacol; 1994 Oct; 46(4):605-11. PubMed ID: 7969039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KN-62 analogues as potent differentiating agents of HL-60 cells.
    Schuler AD; Si J; Mueller L; Simon JA; Collins SJ
    Leuk Res; 2007 May; 31(5):683-9. PubMed ID: 16963120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of M3 muscarinic acetylcholine receptor-mediated Ca2+ influx and intracellular Ca2+ mobilization in neuroblastoma cells by the Ca2+/calmodulin-dependent protein kinase inhibitor 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-trosyl]-4-phenylpiperazin e (KN-62).
    Puhl HL; Raman PS; Williams CL; Aronstam RS
    Biochem Pharmacol; 1997 Apr; 53(8):1107-14. PubMed ID: 9175715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICRF-193 modifies etoposide-induced apoptosis in thymocytes.
    Tanimoto C; Hirakawa S; Kawasaki H; Hayakawa N; Ota Z
    Acta Med Okayama; 1995 Dec; 49(6):281-6. PubMed ID: 8770236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of voltage-gated Ca2+ channel activity in small cell lung carcinoma by the Ca2+/calmodulin-dependent protein kinase inhibitor KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperaz ine) .
    Williams CL; Porter RA; Phelps SH
    Biochem Pharmacol; 1995 Dec; 50(12):1979-85. PubMed ID: 8849323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C.
    Ritke MK; Murray NR; Allan WP; Fields AP; Yalowich JC
    Mol Pharmacol; 1995 Nov; 48(5):798-805. PubMed ID: 7476909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations.
    Suzuki H; Tarumoto Y; Ohsawa M
    Mutagenesis; 1997 Jan; 12(1):29-33. PubMed ID: 9025094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
    Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
    Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dependence of insulin secretion from permeabilized pancreatic beta-cells on the activation of Ca(2+)/calmodulin-dependent protein kinase II. A re-evaluation of inhibitor studies.
    Bhatt HS; Conner BP; Prasanna G; Yorio T; Easom RA
    Biochem Pharmacol; 2000 Dec; 60(11):1655-63. PubMed ID: 11077048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.